Key result
PCSK9 inhibition expands beyond antibodies to novel oral agents, vaccines, and gene-editing therapies.
Why the study?
Pharmacological strategies for PCSK9 inhibition are expanding from established monoclonal antibodies and siRNA to novel injectable, oral, and preclinical modalities, alongside emerging applications beyond cardiovascular disease.
This review summarizes the expanding therapeutic landscape of PCSK9 inhibition for LDL-C reduction and cardiovascular protection, highlighting newly approved injectable and oral agents alongside emerging preclinical gene-editing, vaccine, and oncology applications.
Answers are grounded in this paper and cite their sources.
Genetic validation supports PCSK9 inhibition for LDL-C reduction; leaves open optimal long-term strategies and equity in diverse populations.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted proprotein convertase that promotes lysosomal degradation of the hepatic low-density lipoprotein receptor (LDLR), thereby reducing the clearance of circulating low-density lipoprotein cholesterol (LDL-C). Its validation as a therapeutic target is supported by human genetic evidence demonstrating that loss-of-function variants are associated with lifelong reductions in LDL-C and protection against cardiovascular disease. This review examines the biology of PCSK9 and the expanding range of strategies for its pharmacological inhibition, integrating evidence from human genetic studies, clinical trials, and preclinical models, with particular emphasis on translational relevance. The monoclonal antibodies evolocumab and alirocumab substantially reduce LDL-C levels and cardiovascular risk, whereas inclisiran, a small interfering RNA (siRNA), achieves sustained suppression of hepatic PCSK9 synthesis with infrequent dosing. Recent therapeutic advances include the FDA approvals of lerodalcibep, a third-generation injectable PCSK9 inhibitor, and enlicitide decanoate, an orally administered macrocyclic peptide inhibitor. In parallel, nanoparticle-based delivery systems, active PCSK9 vaccination, and CRISPR-based genome editing represent emerging therapeutic strategies that remain largely in preclinical development. Beyond cardiovascular disease, PCSK9 has been implicated in sepsis, cancer, and neurodegenerative, pulmonary, and autoimmune disorders, although the supporting evidence remains heterogeneous and predominantly preclinical. In oncology, experimental findings implicating PCSK9 in tumor immune evasion and modulation of responses to immune checkpoint blockade have prompted its clinical evaluation as a potential adjunct to anticancer therapy. Further prospective clinical studies are required to establish the efficacy and long-term safety of novel PCSK9-targeted approaches and determine whether their therapeutic potential translates into meaningful clinical benefits.
No takes yet. Share an insight, caveat, or question.
Papagiannidou et al. (2026) conducted a review in Cardiovascular disease and dyslipidemia (elevated LDL-C), as well as sepsis, cancer, neurodegenerative, pulmonary, and autoimmune disorders. PCSK9 inhibitors (evolocumab, alirocumab, inclisiran, lerodalcibep, enlicitide decanoate, and emerging strategies including nanoparticles, vaccines, and CRISPR genome editing) was evaluated. PCSK9 inhibition has expanded from monoclonal antibodies and siRNA to newly FDA-approved agents (lerodalcibep, oral enlicitide decanoate) and preclinical vaccination and gene-editing strategies.
Synapse has enriched 10 related papers. Consider them for comparative context: